BBV 152
Alternative Names: BBV-152; BBV152D; Coronavirus vaccine-ICMR/BBIL; COVAXIN; COVID-2019 vaccine - Bharat Biotech International/Indian Council of Medical Research; Whole-Virion Inactivated SARS-CoV-2 VaccineLatest Information Update: 16 Jan 2023
At a glance
- Originator Bharat Biotech; The Indian Council of Medical Research
- Developer Bharat Biotech; Ocugen; The Indian Council of Medical Research
- Class COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 09 Jan 2023 Efficacy and adverse events data from phase II/III trial in COVID-2019 infections were released by Ocugen
- 22 Sep 2022 Ocugen completes an expanded-access programme for COVID-19 infection (In adults, In the elderly, Prevention) in US (NCT05541289)
- 15 Sep 2022 Ocugen initiates an expanded-access programme for COVID-19 infection (In adults, In the elderly, Prevention) in US (NCT05541289)